NewEdge Advisors’s Co-Diagnostics CODX Stock Holding History

NewEdge Advisors’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19	Hold	6	–	–	﹤0.01%	4166
2026 Q1	$11	Sell	6 -1	-14%	-$3	﹤0.01%	4112
2025 Q4	$34	Hold	7	–	–	﹤0.01%	4180
2025 Q3	$69	Hold	7	–	–	﹤0.01%	4042
2025 Q2	$56	Hold	7	–	–	﹤0.01%	3926
2025 Q1	$62	Hold	7	–	–	﹤0.01%	3845
2024 Q4	$150	Hold	7	–	–	﹤0.01%	3758
2024 Q3	$250	Hold	7	–	–	﹤0.01%	3668
2024 Q2	$250	Hold	7	–	–	﹤0.01%	3635
2024 Q1	$224	Hold	7	–	–	﹤0.01%	3664
2023 Q4	$266	Hold	7	–	–	﹤0.01%	3582
2023 Q3	$212	Hold	7	–	–	﹤0.01%	3321
2023 Q2	$222	Hold	7	–	–	﹤0.01%	3376
2023 Q1	$296	Hold	7	–	–	﹤0.01%	3286
2022 Q4	$1	Buy	+7	New	+$655	﹤0.01%	3991

Other funds holding CODX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAG

Private Advisory Group Redmond, Washington $1.85B AUM 50.66% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors's CODX Position: Q2 2026 in Review

NewEdge Advisors held its Co-Diagnostics (CODX) position steady in Q2 2026 at 6 shares worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #4166.

NewEdge Advisors first reported a position in CODX in Q4 2022 and has held it in 15 quarters since. The position peaked at $296 in Q1 2023. 24 funds tracked by Wall St. Rank hold CODX as of Q2 2026.

NewEdge Advisors held 6 shares of Co-Diagnostics worth $19 as of Q2 2026.
NewEdge Advisors left its Co-Diagnostics share count unchanged in Q2 2026.
Co-Diagnostics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #4166 holding.
NewEdge Advisors first reported a position in Co-Diagnostics in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's Co-Diagnostics position peaked at $296 in Q1 2023.
24 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.